MMIT - Managed Markets Insight & Technology

15/01/2026

https://vist.ly/4mvrh | Determining whether a therapy is covered shouldn't be a matter of guesswork. In this infographic, see how both pharma and HIT companies can leverage BIN/PCN/Group data to pinpoint coverage with precision—down to the formulary and restriction level.

14/01/2026

Too often, development choices are made without understanding coverage and barriers to access. MMIT will be onsite at helping commercial and market access teams ensure the evidence generated during trials truly supports future coverage and adoption.

Schedule a meeting with us at : https://vist.ly/4mrpg

14/01/2026

What can pharma companies expect in 2026? https://vist.ly/4mr3b

In this Q&A, three MMIT access experts share what to look out for, from the role of AI in payer policy development to the growth of value-based contracting for high-volume medications.

13/01/2026

What if you could access the most comprehensive rare disease insights in one place? https://vist.ly/4mkej

Our new exclusive content hub brings together expert perspectives, data-driven analysis, and stories that matter—designed for those shaping the future of rare disease care. Explore what you’ve been missing at the link in this post.

12/01/2026

Payers continue to expand copay accumulator and maximizer programs, but manufacturers still have opportunities to protect patient access and ensure PAP sustainability. MMIT’s Heather Roulston explores options for manufacturers, from specialty pharmacy collaboration to outcomes-driven legislative pressure. https://vist.ly/4mgcz

12/01/2026

Many manufacturers struggle to align disease-state education with the patients who need it most. https://vist.ly/4mfnj

In this use case, learn how MMIT used NorstellaLinQ to isolate high-value patient cohorts across structured and unstructured EMR data—enabling smarter account-level targeting and more impactful education strategies.

09/01/2026

https://vist.ly/4m87h | As payer policies become more restrictive, providers are more likely to forego the access fight and opt for covered therapies. In this Q&A blog, our market access experts share predictions for how the landscape will evolve in 2026.

09/01/2026

https://vist.ly/4m64v | Free-text data creates chaos, conflicting plan names, duplicates, poor match rates, and wasted time chasing the wrong coverage policies. MMIT’s BIN/PCN/Group (BPG) data eliminates the guesswork. Accurate and scalable plan identification helps you save time, reduce errors, make smarter market access decisions, and drive stronger payer pull-through strategies. Identify coverage faster, cut administrative burden, and accelerate your strategy. Connect with an MMIT expert today.

08/01/2026

https://vist.ly/4kzar | From screening patterns to commercialization and physician targeting, discover how MMIT and NorstellaLinQ’s integrated structured and unstructured data can bring clarity to rare disease treatment, bringing you closer to the patient than ever before.

Explore our collection of real-world use cases and expert insights today.

07/01/2026

RWD is transforming how pharma plans for access. At , we’ll show market access teams how integrated, linked data uncovers unmet need, identifies hard-to-reach populations, and more.

Schedule a meeting with us at : https://vist.ly/4kvca

06/01/2026

At MMIT, we recognize that a centralized data experience can eliminate the need for disconnected tools and create stronger alignment in a digitally innovative industry. 📊

With the MMIT Platform, we’ve transformed the user experience. Everything now lives in one place, providing role-based access, a consistent design, and seamless navigation.

🔍 The MMIT Platform. Everything you need. In one place. https://vist.ly/4kpnw

MMIT’s Platform is a strategic leap forward—built to streamline how commercialization teams access insights, execute workflows, and make decisions.

05/01/2026

Employee Spotlight! Associate solution consultant Julia Scanlan is careful not to overwhelm potential clients with too much information about our solutions all at once. As a former market research analyst, she is well-versed in the nuances of MMIT’s datasets. https://vist.ly/4kknm